迪哲医药股东会通过H股上市及多项重要议案

Core Viewpoint - The company, Dize (Jiangsu) Pharmaceutical Co., Ltd., is advancing its international capital strategy by approving the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, marking a significant step in its growth and expansion [1] Group 1: Shareholder Meeting Decisions - The company held its first extraordinary general meeting of 2026 on January 9, where multiple important resolutions were approved [1] - Key decisions included the approval of the H-share issuance plan, amendments to the company’s articles of association, and changes to registered capital to facilitate the listing [1] - The meeting also approved the distribution plan for retained earnings prior to the issuance, the appointment of a listing audit firm, and the establishment of a primary business address in Hong Kong [1] Group 2: Voting and Approval Details - The resolutions were supported by shareholders holding 64.4445% of the total voting rights, with all proposals receiving high approval [1] - Eight resolutions related to the H-share issuance and amendments to the articles of association were passed as special resolutions, each receiving over two-thirds approval from the voting rights present [1] Group 3: Strategic Implications - The decisions made during the shareholder meeting lay a crucial legal and decision-making foundation for the company's Hong Kong listing plan [1] - This marks an important milestone in the company's internationalization efforts and capital strategy [1]